Johnson & Johnson Innovative Medicine

At Johnson & Johnson Innovative Medicine, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Johnson & Johnson Innovative Medicine

April 24, 2024

Using patient data to enable personalized healthcare, ATHENA shows us how!

Personalized healthcare is characterized by tailoring treatments to each individual patient’s needs. Despite evident benefits, implementing such a system is not straightforward. The ATHENA project consortium has successfully devised a set of building blocks to address the challenges associated. Both technological and governance tools were developed that can now be used on a larger scale to catalyze the transition towards personalized medicine and care.

April 24, 2024

Navigating between patient privacy and healthcare innovation

The emergence of artificial intelligence and machine learning accelerates research and innovation across various sectors, particularly in healthcare. The potential for the development of innovative diagnostic tools and therapies based on insights from health data is limitless. However, progress should never compromise the privacy of patients. It’s a delicate balance that is essential to maintain.

February 20, 2024

Optimizing the patient care pathway through data-driven insights

The patient’s journey in a healthcare setting is influenced by factors beyond the mere medical aspects of the case. Local variations in care procedures among hospitals and caregivers enable benchmarking and adaptation of practices to optimize outcomes. For effective process modeling, it’s essential to collect data and extract insights. To optimize this process efficiently, collaborative efforts should explore alternative data sources and implement novel tools.

November 15, 2023

Using real-world data for post-market surveillance of drug safety

After a therapeutic drug hits the market, it is crucial to continuously gather, analyze, and report data regarding its safety and potential side effects, a practice known as pharmacovigilance. Unlike clinical trials, this involves real-world data (RWD), presenting unique challenges in terms of both quality and quantity. The Belgian BELpREG project seeks to employ RWD for monitoring drug utilization during pregnancy and investigating potential safety implications for both maternal and child health. This initiative holds great promise, although it faces substantial hurdles on its path to success.

October 17, 2023

One event, uniting Belgium’s regions

for Johnson & Johnson Innovative Medicine

BioWin and MEDVIA are two Belgian organizations which support and promote health innovation in Wallonia and Flanders. This year, these two clusters have come together to jointly organize the event Science for health on the topic of ‘biology meets technology’. In this dual interview, Ann Van Gysel (MEDVIA) and Sylvie Ponchaut (BioWin) discuss the differences between their regions and how they are working to improve cross-border collaboration in Belgium.

October 17, 2023

Health data standardization: What FHIR can do for you!

Patient data is a treasure trove of information, vital to tailoring individual care pathways and generating profound insights to enhance healthcare more broadly. However, achieving interoperability among the diverse systems employed by various healthcare providers remains a critical challenge. Data standards like FHIR can help to streamline the secure exchange and seamless integration of healthcare data across these different systems. This article will take you through the FHIR framework and how it could be used by your organization.

September 27, 2023

Belgium needs boldness for healthcare innovation

for Johnson & Johnson Innovative Medicine

This year, Science for health will explore the inspiring innovations at the interface of biology and technology. The event will bring together academics, industry leaders, and policymakers to explore the newest treatment platforms and factories of the future. BioVox spoke to Werner Verbiest, member of the event’s Scientific Committee, about the topic and why collaboration is so key right now.

September 27, 2023

Pharmaceutical market access: how real-world data fuel better health beyond clinical trials

Studies of a drug's effectiveness and safety don’t end with clinical trials – they extend beyond market access when the true value of a drug is demonstrated in a real-world setting. Based on this information, factors such as availability, pricing, and reimbursement are adjusted. To study the actual worth of a treatment, we require real-world data (RWD) from a large and diverse patient population. By actively sharing this information with stakeholders, we can fuel further research and innovation, and even help to inform decision-making on a population level. But in order to unlock the full potential of our patient data, all members of the ecosystem have to work together.

August 23, 2023

Jan Rabaey on the convergence of biology and technology

Belgian Prof. Jan Rabaey has spent the past 35 years conducting pioneering tech research at the University of California at Berkeley. His groundbreaking electronics work has been used in a range of modern devices, including the iPad, brain-computer interfaces, and wireless sensor nodes used for the Internet of Things. The ongoing theme of his work has been miniaturization and connection, which he is now using to link technology and people like never before.

June 21, 2023

Advancing the pharmaceutical supply chain using artificial intelligence

Rapidly spreading diseases and unpredictable global shifts cause increased strain to the pharmaceutical supply chain, jeopardizing the secure delivery of drugs to those who are in need. Artificial intelligence can maximize efficacy of the value chain and allow optimal responses to changing market demands. Two experts share insights into the possibilities and hurdles associated with integration of machine learning tools into the pharmaceutical supply chain.